Ireland· IE-PA-EU/1/18/1314/001
Braftovi 50 mg Hard capsule
A encorafenib product containing encorafenib, registered in Ireland by Pierre Fabre Medicament. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Encorafenib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EC03 (encorafenib), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Encorafenib · ATC L01EC03
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of encorafenib costs, country by country.
Normalised to the WHO defined daily dose (0.45 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Encorafenib · price per daily dose (0.45 g)
USD · FX 28 Sept 2026
- CH Switzerland$238.24
The record
At a glance
HPRA (Ireland)- Active substance
- ENCORAFENIB
- Manufacturer
- Pierre Fabre Medicament
- Country
- Ireland (IE)
- ATC code
- L01EC03
- ATC class
- Encorafenib
- Defined daily dose
- 0.45 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/18/1314/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
554 interactions on record for encorafenib.
Graded by severity as the source publishes them — 174 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Encorafenib · interactions on record
554 records
- 174 severe
- 377 moderate
- 3 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- AprepitantA04AD12severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Encorafenib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBRAFTOVIPIERRE FABRE MEDICAMENT, Lavaur
- SwitzerlandBraftovi
- FinlandBraftoviPierre Fabre Medicament
- FranceBRAFTOVI 50 mg, gélulePIERRE FABRE MEDICAMENT
- United KingdomBraftovi 50mg capsulesPierre Fabre Ltd
- IcelandBraftoviPierre Fabre Medicament
- NetherlandsBraftovi 50 mg capsule, hardPierre Fabre Medicament
- NorwayBraftoviPierre Fabre Medicament
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Braftovi
- Liechtenstein · Braftovi
- Norway · Braftovi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4075d284-5a02-49ae-b35b-02ed7a0208bd GET /v1/drugs/4075d284-5a02-49ae-b35b-02ed7a0208bd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, hard",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L01EC03"
],
"strength": null,
"pa_number": "EU/1/18/1314/001",
"substances": [
"ENCORAFENIB"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "20/09/2018",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about encorafenib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.